Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cadi 05

Drug Profile

Cadi 05

Alternative Names: Cadi-05; Immuvac; Leprosy vaccine - National Institute of Immunology; Leprovac; MIP-vaccine-Cadila; Mw-vaccine-Cadila; Mycidac-C; Mycobacterium indicus pranii heat-killed - Cadila; Mycobacterium-indicus-pranii-vaccine-Cadila; Mycobacterium-w-heat-inactivated-Cadila; Mycobacterium-w-heat-killed-Cadila; Mycobacterium-w-vaccine-Cadila

Latest Information Update: 30 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator National Institute of Immunology
  • Developer Cadila Pharmaceuticals
  • Class Attenuated vaccines; Bacterial vaccines; Cancer vaccines
  • Mechanism of Action Desmocollin modulators; Immunostimulants; P38 mitogen-activated protein kinase inhibitors; Toll-like receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Leprosy; Non-small cell lung cancer
  • Phase III Tuberculosis
  • Phase II/III Sepsis
  • Clinical Phase Unknown COVID 2019 infections
  • No development reported Bladder cancer; Head and neck cancer; Multiple myeloma
  • Discontinued Malignant melanoma; Prostate cancer

Most Recent Events

  • 31 May 2020 Cadila Pharmaceuticals phase III trial in COVID-2019 infections (Prevention) in India (Intradermal) in May 2020 (CTRI2020-05-025277)
  • 30 Apr 2020 Clinical trials in COVID-2019 infections in India (Intradermal) (CTRI2020-04-024846)
  • 24 Apr 2020 Cadila Pharmaceuticals plans a phase III trial for COVID-2019 infections in April 2020 (NCT04358809)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top